Antithrombotic Treatment in Antiphospholipid Syndrome: A Review

被引:0
作者
Siniscalchi, Carmine [1 ]
Bernardi, Francesca Futura [2 ]
Di Micco, Pierpaolo [3 ]
Perrella, Alessandro [4 ]
Meschi, Tiziana [1 ]
Trama, Ugo [5 ]
机构
[1] Univ Parma, Dept Internal Med, Internal Med Unit, I-43100 Parma, Italy
[2] Univ Campania Luigi Vanvitelli, Dept Expt Med, Coordinat Reg Hlth Syst, Gen Directorate Hlth Protect, I-80131 Naples, Italy
[3] AFO Med, Interbal Med, ASL Napoli 2 Nord, I-80078 Naples, Italy
[4] UOC Emerging Infect Dis & High Contagiousness, AORN Colli, I-80131 Naples, Italy
[5] Gen Directorate Hlth Protect, Directorate Gen Hlth Protect, Coordinat Reg Hlth Syst, I-80131 Naples, Italy
来源
IMMUNO | 2024年 / 4卷 / 04期
关键词
antiphospholipid syndrome; catastrophic antiphospholipid syndrome; aspirin; heparins; warfarin; direct anticoagulant; INTERNATIONAL CONSENSUS STATEMENT; MOLECULAR-WEIGHT HEPARIN; MONITORING WARFARIN THERAPY; LOW-DOSE ASPIRIN; VENOUS THROMBOEMBOLISM; CLASSIFICATION CRITERIA; LUPUS ANTICOAGULANT; ANTIBODIES; UPDATE; MANAGEMENT;
D O I
10.3390/immuno4040036
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by circulating autoantibodies that recognize cell surface phospholipids and phospholipid-binding proteins. APS is an autoimmune disorder associated with recurrent thrombosis of arterial or venous vessels and/or recurrent obstetric complications as miscarriages. APS can be divided into primary or secondary clinical syndrome because of the possible association with other autoimmune systemic diseases as systemic lupus erythematosus (SLE). Vitamin K antagonists remain the mainstay of treatment for most patients with APS and, based on current data, appear superior to the more targeted direct oral anticoagulants. However, the choice of the type of antithrombotic drug is based on the anamnesis of affected patients: patients with previous arterial or venous thrombosis may benefit from anticoagulants, while patients with previous obstetric diseases may benefit from aspirin, but several clinical exceptions may be evaluated. This short review is dedicated to underlining the main clinical evidence for patients affected by APS or CAPS (catastrophic antiphospholipid syndrome) in order to prevent recurrent thrombosis.
引用
收藏
页码:620 / 628
页数:9
相关论文
共 53 条
[51]  
Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO
[52]  
2-F
[53]   Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial [J].
Woller, Scott C. ;
Stevens, Scott M. ;
Kaplan, David ;
Wang, Tzu-Fei ;
Branch, D. Ware ;
Groat, Danielle ;
Wilson, Emily L. ;
Armbruster, Brent ;
Aston, Valerie T. ;
Lloyd, James F. ;
Rondina, Matthew T. ;
Elliott, C. Greg .
BLOOD ADVANCES, 2022, 6 (06) :1661-1670